Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) had its price target lifted by Truist Financial from $9.00 to $10.00 in a report issued on Monday, Benzinga reports. They currently have a buy rating on the stock.
Separately, The Goldman Sachs Group boosted their price target on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a buy rating in a research report on Monday, May 6th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $9.00.
View Our Latest Stock Analysis on Amneal Pharmaceuticals
Amneal Pharmaceuticals Price Performance
Hedge Funds Weigh In On Amneal Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of AMRX. Rothschild Investment LLC purchased a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at about $26,000. DekaBank Deutsche Girozentrale bought a new position in shares of Amneal Pharmaceuticals in the second quarter worth approximately $42,000. nVerses Capital LLC purchased a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $62,000. Atlanta Consulting Group Advisors LLC bought a new stake in shares of Amneal Pharmaceuticals during the first quarter valued at approximately $61,000. Finally, Xponance Inc. bought a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $65,000. 31.82% of the stock is currently owned by institutional investors.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Featured Stories
- Five stocks we like better than Amneal Pharmaceuticals
- Why Invest in 5G? How to Invest in 5G Stocks
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Ride Out The Recession With These Dividend Kings
- Jeff Brown’s Exegesis AI Stock Picks
- How to Find Undervalued Stocks
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.